Market Overview

OncoSec Medical Offers Updated Long-Term Follow-Up Data From Phase 2 Trial Of ImmunoPulse IL-12 In Combo With Pembrolizumab Showing PFS Of 57% At 15 Months In Predicted Anti-PD-1 Non-Responder Melanoma Patients

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Posted-In: FDA

 

Related Articles

Partner Center